TriangleObinutuzumab (NCT02393157)
Obinutuzumab trial for Non-Hodgkin Lymphoma (NCT02393157). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 3–31 with qualifying CD20-positive B-cell leukemia or lymphoma in first relapse or after initial treatment failure. Prior obinutuzumab is excluded.
The idea: obinutuzumab targets CD20 to attack malignant B cells. It starts before and continues with ifosfamide, carboplatin and etoposide chemotherapy. Liposomal cytarabine enters the spinal fluid for prevention or treatment of central nervous system disease; dosing differs by involvement.
This phase 2 study plans 25 patients. Mitchell Cairo leads at New York Medical College in Valhalla, the sole recruiting US site. Researchers assess safety and response.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.